Related Experiment Videos
Insights
Echocardiograms reveal two distinct patterns of cardiac disease in scleroderma patients: congestive cardiomyopathy and infiltrative cardiomyopathy. These imaging studies aid in early detection and monitoring of myocardial involvement in scleroderma.
Area of Science:
- Cardiology
- Rheumatology
- Medical Imaging
Background:
- Scleroderma, an autoimmune disease, can affect multiple organs, including the heart.
- Cardiac involvement in scleroderma can manifest in various forms, impacting patient prognosis.
- Understanding these cardiac manifestations is crucial for effective management.
Observation:
- Two cases of sclerodermatous cardiac disease are presented.
- Echocardiography was utilized to assess cardiac structure and function in both patients.
- Distinct echocardiographic patterns were identified, reflecting different pathophysiological processes.
Findings:
- The first patient exhibited a congestive cardiomyopathy pattern, characterized by ventricular dilatation and reduced wall motion.
- The second patient presented with an infiltrative cardiomyopathy pattern, showing thickened walls and reduced wall motion without ventricular dilatation.
- Echocardiography successfully differentiated these patterns.
Implications:
- Echocardiographic studies are valuable for the early diagnosis of cardiac involvement in scleroderma.
- These studies can detect both primary and secondary myocardial involvement by scleroderma.
- Echocardiography facilitates monitoring the progression of cardiac disease in scleroderma patients.
Abstract:
The echocardiograms of two patients with sclerodermatous cardiac disease are described. In one patient the pattern was that of a congestive cardiomyopathy with ventricular dilatation and reduced wall motion. In the second patient the pattern was that of an infiltrative cardiomyopathy with thickened walls and reduced wall motion in the absence of ventricular dilatation. Echocardiographic studies are useful in the early detection of pericardial involvement and primary or secondary myocardial involvement by scleroderma and in following the progression of the disease process.